SAN FRANCISCO — In this Healio Video Perspective from the AAO meeting, Renee Bovelle, MD, discusses real-world insights on the use of Dextenza.
An analysis of data from the IRIS Registry revealed that Dextenza (dexamethasone ophthalmic insert 0.4 mg, Ocular Therapeutix) was used more frequently in patients with ocular surface disease and dry eye, suggesting possible prescriber preferences.
In addition, Bovelle discussed the use of Dextenza in patients with cataracts and glaucoma.
“These data emphasize the real-world evidence, informing clinicians of prescribing patterns, and